* Neogenomics Inc NEO.OQ reported quarterly adjusted
earnings of
5 cents per share for the quarter ended September 30, higher
than the same quarter last year, when the company reported
breakeven earnings per share. The mean expectation of
fourteen analysts for the quarter was for earnings of one cent
per share. Wall Street expected results to range from -3 cents
to 5 cents per share.
* Revenue rose 10.4% to $167.82 million from a year ago;
analysts
expected $167.01 million.
* Neogenomics Inc's reported EPS for the quarter was a loss
of 14
cents.
* The company reported a quarterly loss of $17.7 million.
* Neogenomics Inc shares had fallen by 4.1% this quarter and
lost 12.6% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had risen by
about 4.2%
in the last three months.
* In the last 30 days, there have been no negative revisions
of
earnings estimates
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 10 "strong buy" or "buy," 4
"hold" and no "sell" or "strong sell."
* The average consensus recommendation for the healthcare
facilities & services peer group is also "buy"
Wall Street's median 12-month price target for Neogenomics Inc
is $19.50
This summary was machine generated from LSEG data November 6 at
04:53 a.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Sep. 30 2024 0.01 0.05 Beat
Jun. 30 2024 0.00 0.03 Beat
Mar. 31 2024 -0.05 -0.02 Beat
Dec. 31 2023 -0.02 0.03 Beat